Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2016 Commission File Number: 001-37423 Biotie Therapies Oyj (Exact name of registrant as specified in its charter) Biotie Therapies Corp. (Translation of registrant’s name into English) Joukahaisenkatu 6, FI-20520 Turku, Finland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes No Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes No SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BIOTIE THERAPIES CORP. By: Date: June 29, 2016 /s/ David Cook Name: David Cook Title: Chief Financial Officer EXHIBIT INDEX Exhibit Number 99.1 Description Stock Exchange Release dated June 29, 2016 (9:15 a.m. EET): CHANGES IN THE MANAGEMENT TEAM Exhibiy 99.1 BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 29 June 2016, at 9.15 a.m. (EET) CHANGES IN THE MANAGEMENT TEAM Timo Veromaa, President and CEO of Biotie Therapies Corp. (“ Biotie ”, the “ Company ”) David Cook, CFO and Stephen Bandak, CMO of Biotie are leaving the Company by June 30, 2016. The Board of Directors of Biotie has appointed Antero Kallio, M.D., as the new CEO and Kristian Rantala as CFO for the Company, effective July 1, 2016. Antero Kallio is currently the site head of Biotie’s operations in Turku, Finland and Kristian Rantala is vice president finance of the Company. The responsibilities of the Chief Medical Officer will be divided among the Company’s research and development team staff members as well as with Acorda Therapeutics’ interim Chief Medical Officer Burkard Blank, M.D. Timo Veromaa was appointed President and CEO of Biotie in 2005. He has led the company through a number of pivotal transactions, including financial restructurings, acquisition of Synosia Therapeutics Holding AG in 2011 and IPO of Biotie in the US in 2015. “We thank Timo for his expertise, dedication and commitment to Biotie during more than a decade at the helm of the Company. Timo, David and Stephen have been instrumental for the Company during the recent years, in particular in connection with the US listing and fundraise that took place in 2015. We wish Timo, David and Stephen the best in their future endeavours” says Ron Cohen, Chairman of the Board of Directors of Biotie. Turku, 29 June 2016 THE BOARD OF DIRECTORS For further information, please contact: Virve Nurmi, Biotie Therapies Corp. tel. +358 2 274 8900, e-mail: [email protected] DISTRIBUTION: www.biotie.com Nasdaq Helsinki Ltd Main Media INFORMATION REGARDING BIOTIE Biotie is a biopharmaceutical company focused on products for neurodegenerative and psychiatric disorders. Biotie's development has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S. The current development products include tozadenant for Parkinson's disease, which is in Phase 3 development, and two additional compounds which are in Phase 2 development for cognitive disorders including Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of the liver. For more information, please visit www.biotie.com.